Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contezolid plasma and lung penetration study in gram-positive pulmonary infection
ChiCTR2500101413Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of contezolid in pulmonary infection, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: First dose plasma drug concentration, Steady-state plasma drug concentration and 2 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
contezolid
03
Conditions
pulmonary infection
Beyond the preview
Go deeper on ChiCTR2500101413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101413.